Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Post-craniotomy Pain

Sponsor
Beijing Tiantan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04141319
Collaborator
(none)
100
2
12

Study Details

Study Description

Brief Summary

The PAINLESS study is a single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled clinical study to compare the efficacy and safety of pre-emptive scalp infiltration with ropivacaine plus ketorolac and ropivacaine alone for postoperative pain relief in adults undergoing elective supratentorial craniotomies.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

The proposed study will be a single-center, prospective, randomized, open-label, blinded-endpoint clinical trial designed to test the hypothesis that the addition of ketorolac to pre-emptive scalp infiltration analgesia can significantly improve analgesia after craniotomies. One hundred participants will be randomized to the ketorolac group or the control group. Patients in the ketorolac group will receive pre-emptive scalp infiltration with opivacaine,ketorolac and epinephrine while patients in the control group will receive pre-emptive scalp infiltration with ropivacaine and epinephrine.The primary outcome measure will be cumulative doses of patient-controlled analgesia (PCA) butorphanol consumption from 0 to 48 h postoperatively.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS)
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: The ketorolac group

Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.

Drug: Ketorolac
30ml of local infiltration solution containing 60mg ropivacaine

Drug: Ropivacaine
30ml of local infiltration solution containing 6mg ketorolac

Drug: Epinephrine
30ml of local infiltration solution containing 0.1mg epinephrine

Active Comparator: The control group

In the control group, preoperative peri-incisional scalp infiltration will be performed using 30ml of 60 mg ropivacaine and 0.1mg epinephrine.

Drug: Ropivacaine
30ml of local infiltration solution containing 6mg ketorolac

Drug: Epinephrine
30ml of local infiltration solution containing 0.1mg epinephrine

Outcome Measures

Primary Outcome Measures

  1. cumulative doses of patient-controlled analgesia (PCA) butorphanol consumption from 0 to 48 h postoperatively [0 to 48 hours postoperatively]

    The primary outcome measure will be cumulative doses of PCA butorphanol consumption from 0 to 48 h postoperatively

Secondary Outcome Measures

  1. The time to first request for patient-controlled analgesia butorphanol [Within 48hours postoperatively]

    The time to first request for patient-controlled analgesia butorphanol

  2. frequency of pressing patient-controlled analgesia pump [Within 48hours postoperatively]

    frequency of patient-controlled analgesia pump

  3. numeral rating scale (NRS) Score [at 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 1 month, 3 months and 6 months postoperatively]

    0 for"no pain" and 10 for "'pain as severe as you can imagine"

  4. Pain control satisfaction score (PCSS) postoperatively [at 24 hours, 48 hours, 72 hours, 1 week, 1 month, 3 months and 6 months]

    0 for unsatisfactory and 10 for very satisfactory

  5. Ramsay sedation score (RSS) [at 2 hours, 4 hours, 8 hours, 24 hours and 48 hours and 72 hours postoperatively]

    1: Anxious, agitated, restless; Ramsey 2: Cooperative, oriented, tranquil; Ramsey 3: Responsive to commands only If Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to light glabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus. Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to light glabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus.

  6. pulse oxygen saturation(SpO2) [1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively]

    SpO2

  7. mean arterial blood pressure(MAP) [1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively]

    MAP

  8. heart rate(HR) [1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively]

    HR

  9. respiratory rate(RR) [1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively]

    RR

  10. Length of hospital stay [Length of hospital stay, an arverage of 2 weeks]

    Length of hospital stay

  11. Wound healing score [at 3 weeks and 6 weeks after surgery]

    Skin Healing 1: fully healed; 2: ≤3 cm in total not healed; 3: >3 cm not healed; 4: areas of necrosis ≤3 cm; 5: areas of necrosis >3 cm Infection 1: none; 2: ≤0.5-cm margin of redness; 3: more redness or superficial pus; 4: deep infection; not applicable Hair Regrowth 1: even regrowth along wound; 2: ≤3 cm not regrowing; 3: >3-6 cm not regrowing; 4: >6 cm not regrowing; not applicable

  12. postoperative nausea and vomiting(PONV) [within 48 hours postoperatively]

    0, absent; 1, nausea but not requiring treatment; 2, nausea requiring treatment; and 3, vomiting

  13. The presence of respiratory depression [within 48 hours postoperatively]

    respiratory rate <10 breaths per minute or SpO2 was<90 %

  14. The incidence of haematoma, wound infection or gastric ulcers [during hospitalization, within 2 weeks postoperatively]

    side effects

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Scheduled for elective supratentorial tumour resection;

  • Planned general anaesthesia;

  • American Society of Anesthesiologists (ASA) physical status I - II;

  • Age ranging from 18 to 65 years old;

  • Participates required to fix their head in a head clamp intraoperatively;

  • Participates with an anticipated awake within 2 hours after surgery.

Exclusion Criteria:
  • Allergy/intolerance to study drugs including anesthetic drugs, ketorolac and epinephrine;

  • Expected delayed extubation or no plan to extubate;

  • History of neurosurgeries;

  • Long-term use of analgesics and sedatives (more than 2 weeks)

  • Receiving any painkiller within 24 h before the operation;

  • Extreme body mass index (BMI) (less than 15 or more than 35);

  • Patients with impaired cardiopulmonary;

  • Patients with impaired renal function;

  • Patients with impaired hepatic function;

  • History of chronic headache;

  • Patients with cognitive deficit;

  • Patients with intellectual disability;

  • Patients with uncontrolled epilepsy;

  • Patients with psychiatric disorders;

  • Difficulties in using PCA device

  • Difficulties in understanding the use of numeral rating scale (NRS) ;

  • Patients with suspected intracranial hypertension;

  • Pregnant or at breastfeeding;

  • Infection at the incisional site;

  • History of radiation therapy and chemotherapy preoperatively

  • With great likelihood of postoperative radiation therapy and chemotherapy based on preoperative imaging.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Beijing Tiantan Hospital

Investigators

  • Principal Investigator: Fang Luo, M.D, Beijing Tiantan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fang Luo, Director of Department of Pain Management, Beijing Tiantan Hospital
ClinicalTrials.gov Identifier:
NCT04141319
Other Study ID Numbers:
  • KY-2018-034-02-6
First Posted:
Oct 28, 2019
Last Update Posted:
Jan 22, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 22, 2020